welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
Ursodeoxycholic Acid Counteracts Celecoxib in Reduction of Duodenal Polyps in Patients With Familial Adenomatous Polyposis: A Multicentre, Randomized Controlled Trial
source: Orphanet journal of rare diseases
authors: van Heumen B W, Roelofs H M, Vink-Börger M E, Dekker E, Mathus-Vliegen E M, Dees J, Koornstra J J, Langers A M, Nagtegaal I D, Kampman E, Peters W H, Nagengast F Msummary/abstract:
Due to prophylactic colectomy, mortality in patients with familial adenomatous polyposis (FAP) has changed, with duodenal cancer currently being the main cause of death. Although celecoxib reduces duodenal polyp density in patients with FAP, its long-term use may increase the risk of cardiovascular events and alternatives need to be explored. Preclinical studies suggest that the combination of celecoxib with ursodeoxycholic acid (UDCA) is a potentially effective strategy. We performed a randomized, double-blind, placebo-controlled trial to investigate the effect of celecoxib and UDCA co-treatment on duodenal adenomatosis in patients with FAP.
Patients with FAP received celecoxib (400 mg twice daily) and UDCA (1000-2000 mg daily, ~20-30 mg/kg/day, n=19) or celecoxib and placebo (n=18) orally for 6 months. Primary outcome was drug efficacy, assessed by comparing duodenal polyp density at pre- and post-intervention by blinded review of endoscopic recordings. As secondary outcomes, cell proliferation, apoptosis, and COX-2 levels in normal duodenal mucosa were assessed by immunohistochemistry or real-time quantitative polymerase chain reaction.
In intention-to-treat analysis, deceased polyp density was observed after celecoxib/placebo treatment (p=0.029), whereas increased polyp density was observed after celecoxib/UDCA treatment (p=0.014). The difference in change in duodenal polyp density was statistically significant between the groups (p=0.011). No changes in secondary outcomes were observed. Thirty patients (81%) reported one or more adverse events, 16 patients (84%, Common Toxicity Criteria for Adverse Events version 3.0 (CTCAE) grade 1-3) treated with celecoxib/UDCA and 14 patients (78%, CTCAE grade 1-2) treated with celecoxib/placebo. Nine patients (24%) discontinued intervention prematurely, 5 patients (26%) treated with celecoxib/UDCA and 4 patients (22%) treated with celecoxib/placebo.
Celecoxib reduces duodenal polyp density in patients with FAP, and unexpectedly, high dose UDCA co-treatment counteracts this effect. The benefit of long term use of celecoxib for duodenal cancer prevention needs to be weighed against the (risk of) adverse events.
read more full text source
expertly curated content related to this topic
Searchable Interface for Patient Education Information – Familial Adenomatous Polyposis (FAP)Familial Adenomatous Polyposis (FAP) is ...
Restorative Proctocolectomy and Ileal Pouch-Anal Anastomosis in ChildrenPURPOSE : This study was designed to eva...
Effects of Intervention with Sulindac and Inulin/vsl#3 on Mucosal and Luminal Factors in the Pouch of Patients with ...BACKGROUND/AIM: In order to define futu...
Intestinal Polyps and Polyposis: State-of-the-Art, Multidisciplinary Publication on Polyps and PolyposisNowadays, we are dealing more frequently...
Chemoprevention of hereditary colon cancers: time for new strategiesColorectal cancer (CRC) is potentially p...
Prevalence of Small Bowel Polyps in Patients With Sporadic Duodenal AdenomasLittle is known about the prevalence of ...
A Clinical Trial of COX and EGFR Inhibition in Familial Polyposis PatientsThe purpose of this study is to determin...